Umecrine Cognition, a Karolinska Development’s portfolio company recently carried out clinical phase 2a study of golexanonole, a drug candidate in the clinical development for hepatic encephalopathy (HE) and intends to deliver its results on November 13–16, 2020 at the conference “The Liver Meeting Digital Experience”.
The drug candidate golexanolone by Umecrine Cognition is a novel orally-active GABAA receptor that modulates steroid antagonist is targeting the debilitating symtoms of hepatic encephalopathy. The company will present these results of conducted clinical phase 2a study at The Liver Meeting which is a world’s largest conference on hepatic medicine field.
While in the latest development before the meeting, scientific abstract of the study results by Umecrine Cognition attained the rank in the top 10 percent and has been selected as a “Poster of Distinction”. AALSD will give Umecrine Cognition the special recognition.
Karolinska Development CEO, Viktor Drvota said, “We are glad that the results from Umecrine Cognition’s clinical study are received with such interest and that the company is being noticed as an important actor at one of the largest conferences in the field.”